Navigation Links
Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
Date:7/7/2010

EAST NORRITON, Pa., July 7 /PRNewswire-FirstCall/ -- Tengion Inc. (Nasdaq: TNGN) today announced that it has appointed Sunita B. Sheth, M.D., to the position of Chief Medical Officer, Vice President, Clinical and Regulatory Affairs. In this role, Dr. Sheth will be responsible for developing clinical development strategies, implementing clinical trials, and providing clinical translation insights to preclinical pipeline programs.

"We are extremely pleased to add Dr. Sheth to the Tengion team," stated Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion. "Her broad experience in multiple therapeutic areas, deep knowledge of early and late stage clinical development, and commitment to patient care will be invaluable to Tengion as we continue to advance our platform and product candidates."

Dr. Sheth most recently served as Vice President, Specialty Care Business Unit, for Pfizer as part of its acquisition of Wyeth. Prior to that, she spent four years at Wyeth, most recently as Vice President, Cardiovascular, Metabolic and Infectious Diseases. Before joining Wyeth, she held positions of increasing responsibility at AstraZeneca and GlaxoSmithKline since joining the industry in 1997. Her pharmaceutical development leadership experience covers multiple therapeutic areas and phases of development including approval of several INDs for drugs as well as the biologics FIX mab and OAP-189; the global regulatory submission of ximelagatran for multiple indications; and approval of an sNDA for Tygacil. 

"This is an exciting time for Tengion and I am very much looking forward to working closely with the management team to advance the company's pipeline," stated Dr. Sheth. "Tengion's Organ Regeneration Platform™ provides a unique opportunity to bring novel therapies and clinical advances to patients in need."

Dr. Sheth earned her B.A. and M.D. degrees from Brown University and completed fellowships in Hematology/Oncology at Brown and Temple University. She maintains an adjunct professorship at Temple University Medical School.

Tengion's lead program, the Neo-Urinary Conduit™, is currently in a Phase 1 clinical trial in patients with bladder cancer. Tengion expects to report key data for its lead discovery program, the Neo-Kidney Augment™, later this year.

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform that enables us to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Our product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. Tengion commenced a Phase I clinical trial in March 2010 for its lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder issue for bladder cancer patients requiring a urinary diversion following bladder removal. Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder. Tengion has worldwide rights to its product candidates.

Forward-Looking Statements

Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to: (i) our plans to develop and commercialize our product candidates, including our Neo-Urinary Conduit; and (ii) our ongoing and planned preclinical studies and clinical trials. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and the company's business is subject to significant risk and uncertainties, and there can be no assurance that its actual results will not differ materially from its expectations. These risks and uncertainties include, among others: (i) we may have difficulty enrolling patients in our clinical trials, including our Phase I clinical trial for our Neo-Urinary Conduit; (ii) patients enrolled in our clinical trials may experience adverse events related to our product candidates, which could delay our clinical trials or cause us to terminate the development of a product candidate; and (iii) we may be unable to progress our product candidates that are undergoing preclinical testing into clinical trials. For further information with respect to factors that could cause the company's actual results to differ materially from expectations, reference is made to the reports the company filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and the company disclaims any intention or responsibility for updating predictions or expectations contained in this release.


'/>"/>
SOURCE Tengion Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. West Pharmaceutical Services, Inc. Appoints New Director
7. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
8. Curemark Appoints Preeminent Pediatrics Gastroenterologist
9. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
10. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
11. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... surveys with 9,250 insured consumers fielded from February 2015 ... help from their plans in five key areas: 1) ... help closing gaps in care, 3) better digital connections, ... real-time guidance. Meeting these needs is essential to promoting ... A Reason to Stay Engaged in Health ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... The Global Cryostat Market ... the next decade to reach approximately $3.5 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:3/23/2017)... , March 23, 2017 ... report created through extensive primary research (inputs from ... report aims to present the analysis of global ... Procedure (Replacement and Repair); Replacement Procedure By Technique ... By Technique (Surgical Devices, Balloon Valvuloplasty, Transcatheter Mitral ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion ... real people of God in congregations across the United States. “The Communion ... ordained in 1964 who has served congregations in seven states throughout his long ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... In 2016 ... now estimates that there could be four million Zika-related cases in the Americas within ... with numbers of US cases reported per year skyrocketing to an estimated 329,000. Yet, ...
(Date:3/23/2017)... ... ... The physicians of KSF Orthopaedic Center PA are proud to announce the opening ... at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside the new ... in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with an even ...
(Date:3/23/2017)... Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... new clinic, located at 960 Gruene Road in Building 2. The clinic is the ... Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The IoT ... and WiFi connectivity are making a huge impact on businesses and individual consumers alike. ... estimates the IoT will have a value anywhere from $4 trillion to $11 trillion ...
Breaking Medicine News(10 mins):